A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

To be able to join this study, you must have already taken part in one of the previous Sonelokimab studies for Hidradenitis Suppurativa (named M1095-HS-301, M1095-HS-302, or M1095-HS-304) and been suitable to continue receiving the medicine when your previous study ended.

There are also some very important rules for who can’t take part. You won’t be able to join if you had to stop your previous study for any specific safety or medical reasons. Also, if you’re currently using or planning to use other particular treatments for HS or other conditions that aren't allowed in the study, you wouldn’t be eligible. Lastly, if you're planning to take part in another medical study for a drug or device at the same time, this study wouldn't be right for you.

If you are female, you must not be pregnant or breastfeeding. If you are male, you must agree to use a condom if you're sexually active with a female partner who could become pregnant, and you must agree not to donate sperm during the study and for at least 8 weeks after your last dose of the study medicine.

Taking part in this study means you would continue to receive the Sonelokimab medicine, likely given by an injection under the skin (subcutaneous). You would have regular visits to the clinic where the study team would check your health, assess your HS symptoms, and monitor for any side effects. They might take blood samples or perform other examinations, similar to what you might have experienced in your previous study. The study team will explain how often these visits would be and what each visit would involve. They will also keep track of how you are feeling and if the medicine is helping your HS over time. The total duration of your participation would be explained in detail by the study team.